Published in PLoS One on January 25, 2017
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 4.41
Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc Natl Acad Sci U S A (2002) 4.00
Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med (2003) 3.81
Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med (2005) 3.72
Combination of FASP and StageTip-based fractionation allows in-depth analysis of the hippocampal membrane proteome. J Proteome Res (2009) 3.56
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 3.42
Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2010) 3.37
MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med (2008) 2.79
Proteome and proteomics: new technologies, new concepts, and new words. Electrophoresis (1998) 2.42
ATS/ERS/WASOG statement on sarcoidosis. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. Eur Respir J (1999) 2.20
C-reactive protein and risk of lung cancer. J Clin Oncol (2010) 1.90
Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2009) 1.80
Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis. Thorax (2014) 1.76
Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 1.75
Serum surfactant proteins A and D as prognostic factors in idiopathic pulmonary fibrosis and their relationship to disease extent. Am J Respir Crit Care Med (2000) 1.72
Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J (2002) 1.63
Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest (2009) 1.50
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the Subcommittee on Hypersensitivity Pneumonitis. J Allergy Clin Immunol (1989) 1.35
MMP expression and abnormal lung permeability are important determinants of outcome in IPF. Eur Respir J (2008) 1.17
Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology (2009) 1.16
Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis. Am J Respir Crit Care Med (2010) 1.13
Effects of hemolysis interferences on routine biochemistry parameters. Biochem Med (Zagreb) (2011) 1.12
Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med (2012) 1.09
Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl Res (2012) 1.08
The peripheral blood transcriptome identifies the presence and extent of disease in idiopathic pulmonary fibrosis. PLoS One (2012) 1.07
C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2014) 1.03
Idiopathic pulmonary fibrosis: from epithelial injury to biomarkers--insights from the bench side. Respiration (2013) 1.00
Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2014) 0.99
Increased expression of YKL-40, a chitinase-like protein, in serum and lung of patients with idiopathic pulmonary fibrosis. Respir Med (2010) 0.96
Idiopathic pulmonary fibrosis: current and future treatment options. Am J Respir Med (2002) 0.96
Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis. Chest (2013) 0.93
Matrix Metalloproteinases as Therapeutic Targets for Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol (2015) 0.92
Using Galaxy-P to leverage RNA-Seq for the discovery of novel protein variations. BMC Genomics (2014) 0.92
Serum heat shock protein 47 levels are elevated in acute exacerbation of idiopathic pulmonary fibrosis. Cell Stress Chaperones (2013) 0.91
Pepsin concentrations are elevated in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis after lung transplantation. J Surg Res (2013) 0.91
Plasminogen activator inhibitor-1 promotes the proliferation and inhibits the apoptosis of pulmonary fibroblasts by Ca(2+) signaling. Thromb Res (2012) 0.90
Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. Treat Respir Med (2006) 0.90
Clinical implication of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Respir Med (2012) 0.88
Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension. J Korean Med Sci (2010) 0.87
Significance of serum vascular endothelial growth factor level in patients with idiopathic pulmonary fibrosis. Lung (2010) 0.86
Acute exacerbations of idiopathic pulmonary fibrosis. Respiration (2013) 0.86
Plasminogen activator inhibitor-1 suppresses profibrotic responses in fibroblasts from fibrotic lungs. J Biol Chem (2015) 0.86
Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med (2016) 0.85
[Outcome of patients with acute exacerbation of idiopathic interstitial fibrosis (IPF) treated with sivelestat and the prognostic value of serum KL-6 and surfactant protein D]. Nihon Kokyuki Gakkai Zasshi (2007) 0.85
Baseline KL-6 predicts increased risk for acute exacerbation of idiopathic pulmonary fibrosis. Respir Med (2014) 0.85
New frontiers in proteomics research: a perspective. Int J Pharm (2005) 0.84
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis. Chest (2014) 0.84
Personalized medicine in idiopathic pulmonary fibrosis: facts and promises. Curr Opin Pulm Med (2015) 0.83
S100A9 in BALF is a candidate biomarker of idiopathic pulmonary fibrosis. Respir Med (2011) 0.83
Epigenetics of idiopathic pulmonary fibrosis. Transl Res (2014) 0.83
Grainyhead-like 2 (GRHL2) distribution reveals novel pathophysiological differences between human idiopathic pulmonary fibrosis and mouse models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2013) 0.81
The elevation of serum napsin A in idiopathic pulmonary fibrosis, compared with KL-6, surfactant protein-A and surfactant protein-D. BMC Pulm Med (2012) 0.81
[The expressions and meanings of BMP-7 and TGF-β in idiopathic pulmonary fibrosis and idiopathic nonspecific interstitial pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi (2014) 0.81
Serum biomarkers in idiopathic pulmonary fibrosis. Pulm Pharmacol Ther (2010) 0.81
Pathogenesis of pulmonary fibrosis in systemic sclerosis: lessons from interstitial lung disease. Curr Rheumatol Rep (2010) 0.81
MRP14 is elevated in the bronchoalveolar lavage fluid of fibrosing interstitial lung diseases. Clin Exp Immunol (2010) 0.81
CCN5 overexpression inhibits profibrotic phenotypes via the PI3K/Akt signaling pathway in lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis and in an in vivo model of lung fibrosis. Int J Mol Med (2013) 0.81
Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers. Respirology (2015) 0.80
Abnormal expression of IGF-binding proteins, an initiating event in idiopathic pulmonary fibrosis? Pathol Res Pract (2010) 0.80
Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease. Respir Res (2014) 0.79
Medical Therapy in Idiopathic Pulmonary Fibrosis. Semin Respir Crit Care Med (2016) 0.79
Mononuclear phagocytes and airway epithelial cells: novel sources of matrix metalloproteinase-8 (MMP-8) in patients with idiopathic pulmonary fibrosis. PLoS One (2014) 0.79
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC Med (2015) 0.79
Advances in the study of biomarkers of idiopathic pulmonary fibrosis in Japan. Biosci Trends (2013) 0.79
iTRAQ technology-based identification of human peripheral serum proteins associated with depression. Neuroscience (2016) 0.78
Local C-reactive protein expression in obliterative lesions and the bronchial wall in posttransplant obliterative bronchiolitis. Mediators Inflamm (2009) 0.78
Idiopathic pulmonary fibrosis. Expert Rev Respir Med (2007) 0.78
Molecular biomarkers in idiopathic pulmonary fibrosis and disease severity. Sarcoidosis Vasc Diffuse Lung Dis (2013) 0.76
[The relationship between inflammatory mediators and pulmonary hypertension in patients with chronic obstructive pulmonary disease]. Zhonghua Jie He He Hu Xi Za Zhi (2011) 0.75